Treatment of multiple sclerosis with newer immune-modulating drugs

Australian Prescriber

Volumn 25, Issue 2, 2002, Pages 32-35

  Taylor, Isabella ^a   Macdonell, Richard ^a,b   Coleman, Jennifer ^c  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c NONE

Author keywords

Glatiramer acetate; Interferon beta

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; METHOTREXATE;

BRAIN ATROPHY; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DRUG CONTRAINDICATION; FLU LIKE SYNDROME; HUMAN; IMMUNOMODULATION; MULTIPLE SCLEROSIS; RELAPSE; REVIEW; SIDE EFFECT; SKIN ULCER;

EID: 0036225218     PISSN: 03128008     EISSN: None     Source Type: Journal    
DOI: 10.18773/austprescr.2002.033     Document Type: Review

References (16)

1. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis
2. Interferon beta-1 b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double blind, placebocontrolled trial
3. Intramuscular interferon beta-1 a for disease progression in relapsing multiple sclerosis
4. Randomized double-blind placebo-controlled study of interferon beta-1 a in relapsing/remitting multiple sclerosis
5. Copolymer 1 reduces relapse rate and improves disability in relapsingremitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial
6. Should all patients with an initial diagnosis of multiple sclerosis be treated with beta interferon?
7. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsingremitting MS
8. Placebo-controlled multicentre randomised trial of interferon beta-1 b in treatment of secondary progressive multiple sclerosis
9. Randomized controlled trial of interferonbeta-1 a in secondary progressive MS: MRI results
10. The ups and downs of multiple sclerosis therapeutics
11. Management of patients receiving interferon beta-1 b for multiple sclerosis: Report of a consensus conference
12. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1
13. A prospective, open-label treatment trial to compare the effect of IFNbeta-1 a (Avonex), IFNbeta-1 b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: Results after 18 months of therapy
14. Double-blind randomized multicenter dose-comparison study of interferonbeta-1 a (AVONEX): Rationale, design and baseline data
15. Evidence of interferon beta-1a dose response in relapsing-remitting MS: The OWIMS Study. The Once Weekly Interferon for MS Study Group
16. European/Canadian multicenter, doubleblind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging - Measured disease activity and burden in patients with relapsing multiple sclerosis